Premium
Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat
Author(s) -
Sperti Cosimo,
Militello Carmelo,
Behboo Roubik,
Khajeturian Edwin,
Pedrazzoli Sergio,
Perasole Antonio,
Alaggio Rita,
Rovati Lucio
Publication year - 1994
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930570105
Subject(s) - cholecystokinin , proglumide , antagonist , medicine , cholecystokinin receptor , endocrinology , receptor
The effects of the cholecystokinin (CCK)‐analogue, caerulein, and CCK‐receptor antagonist lorglumide (CR‐1409) on pancreatic carcinogenesis induced by 7,12‐dimethylbenz(a)anthracene (DMBA) were studied. One hundred thirty rats were divided into the following 10 treatment groups: group 1, DMBA (2–3 mg); group 2, DMBA + caerulein (5 μg/kg); group 3, DMBA + caerulein + CR‐1409 (12 mg/kg); group 4, caerulein + DMBA; group 5, caerulein + CR‐1409 + DMBA; group 6, DMBA + CR‐1409; group 7, CR‐1409 + DMBA; group 8, caerulein; group 9, CR‐1409; and group 10, sham operation + saline. DMBA was surgically implanted into the pancreas. Caerulein and/or CR‐1409 was administered twice daily for 15 days after (in groups 2, 3, and 6) or before (in groups 4, 5, and 7) DMBA implantation. Six months after carcinogen administration, all rats were sacrificed and autopsied. The incidence of pancreatic cancer appeared significantly ( P < 0.001) increased when caerulein was administered following DMBA implantation. CR‐1409 significantly inhibited ( P < 0.02) caerulein effects and reduced tumor growth when injected after carcinogen exposure. © 1994 Wiley‐Liss, inc.